Over the past two decades, approaches to targeted coagulation therapy in vivo have largely focused on selective delivery of the extracellular domain of the coagulation-inducing protein tissue factor (truncated tissue factor, tTF, the initiator of the extrinsic pathway of blood coagulation) to tumor vessels, by using antibody or peptide ligands that recognize various tumor endothelial markers [1–7]. The gene discussed is F3; the disease is neoplasm.